New Bimzelx information sheet available

As part of our ongoing commitment to providing good quality and accurate information, The Psoriasis Association have recently produced a new information sheet on Bimzelx which is now available.

Bimzelx, (also referred to by its generic name, Bimekizumab) is a biologic medication that is used to treat severe psoriasis. It has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and it is recommended by the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) to treat severe psoriasis (or if you cannot take, or if your psoriasis has not responded well to systemic treatments including ciclosporin, methotrexate and phototherapy) in England, Wales and Scotland.

Bimzelx is also recommended by the National Institute for Health and Care Excellence (NICE) to treat active psoriatic arthritis (PsA) in adults whose condition has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them.

The new leaflet, which sets out all of the key information about the medication including how it works, who it is for and how it will be administered, has been through a robust production process in line with the requirements of the PIF Tick, the only UK quality mark for trustworthy health information.

The Psoriasis Association has received PIF Tick accreditation for the last three years meaning that all of our information resources that carry the PIF logo have demonstrated they meet the ten criteria set out by the scheme, one of which is that the resource should be thoroughly reviewed by both expert and lay reviewers.

We currently provide over 50 information sheets and resources for people who want to find out more about psoriasis and the issues that people with psoriasis and psoriatic arthritis face in their daily lives.

You can access the new Bimzelx information resource here or please contact mail@psoriasis-association.org.uk to request a hard copy.